脑机接口产业白皮书 2026半导体应用技术范式下的全球竞争与中国弯道超车

脑机接口产业白皮书 2026・半导体应用技术范式下的全球竞争与中国弯道超车（报告版本V1.9）

报告日期：2026年7月26日

报告等级：Institutional Core Deep Dive｜机构核心重仓深度报告

报告编号：ZYS-202607280-CDYD001-B03

覆盖标的：脑机接口

出具日期：2026.08.05

出品机构：渣学院·臻研社｜Global Pharma Strategy Research

首席分析师：阳晴（Global Innovative Pharma Lead Analyst）

服务团队：苏慧果李珂佳丁美娟

报告复核：项中原李俊

核心覆盖维度：#Global DEL Platform Leader #Drug Discovery Infrastructure #Dual Model Cashflow & Pipeline Option #Multi-Technology Synergy #AI+Automation Iteration #Global Client Moat

Research Orientation：Global Industrial Paradigm Research｜Cross-Border Value Restructuring Observation

Core Research Dimension：脑机接口终局变革 / DEL技术渗透周期 / 平台型CXO商业模式 / 全球化客户壁垒 / 自研管线价值兑现 / 估值体系重构

Report No.：ZY-BCI-20260701Research Rating｜Global Tier-0 Institutional Exclusive Whitepaper (Global Top-Tier Biotech Semiconductor Offshore Pricing Manuscript)

PARADIGM UPGRADE STATEMENT｜范式升级声明

English：This manuscript puts forward a disruptive cross-industry research paradigm for Brain-Computer Interface (BCI), completely stripping BCI from the traditional medical device valuation logic dominated by global brokerages and reconstructing a brand-new industrial pricing system based on semiconductor engineering dimensions. Mainstream global financial institutions uniformly adopt shallow research logic centered on medical indication expansion, PEG valuation and clinical progress tracking, unable to identify the core semiconductor essence of BCI signal chains, nor quantify the long-term industrial value driven by wafer process roadmap, channel number Moore’s Law and advanced packaging iteration. This research builds three original top-tier investment research systems including Technology-Capital-Policy Triangular Verification Framework, BCI Channel-Process Node Global Mapping Model, and Cognitive Arbitrage Three-Stage Pricing System, together with patent entropy quantitative analysis model and cross-border China-US-Europe three-party industrial benchmarking system. It completes the paradigm shift from "medical device post-event performance interpretation" to "semiconductor industrial forward-looking valuation, long-cycle channel capacity ceiling anchoring, global standard right competition deduction", providing a systematic theoretical allocation basis for offshore long-term technology capital, medical industrial capital and cross-border sovereign innovation funds to deploy global BCI bi-semiconductor assets.

中文：本研究提出颠覆性跨行业脑机接口（BCI）研判范式，将 BCI 从全球券商主导的传统医疗器械估值叙事中彻底剥离，重构基于半导体工程维度的全新产业定价体系。全球主流金融机构统一采用以适应症拓展、PEG 估值、临床进度跟踪为核心的浅层研究逻辑，无法识别 BCI 信号链路底层半导体本体属性，亦不能量化晶圆制程路线图、通道数摩尔定律、先进封装迭代驱动的长期产业价值。本文落地三大原创顶级投研体系，涵盖「技术 - 资本 - 政策」三角验证框架、BCI 通道 - 制程节点全球映射模型、认知套利三阶段定价体系，配套专利熵量化分析模型、中美欧三方产业对标体系，完成从传统「医疗器械事后业绩解读」到「半导体产业前瞻估值、长周期通道容量天花板锚定、全球标准话语权博弈推演」的范式跃迁，为离岸长线科技资本、医疗产业资本、跨境主权创新资金配置全球 BCI 生物半导体资产，提供成体系理论框架与配置依据。

DISCLAIMER｜免责声明（学术合规强化版）

English：This manuscript focuses on quantitative deduction of BCI industrial endgame value and semiconductor technical model derivation, abiding by the analytical paradigm of semiconductor industrial economics and long-cycle frontier technology research, and does not constitute any stock recommendation, trading guidance or investment decision basis. All pricing logics, industrial comparison conclusions and technical route forecasts are only for academic and industrial research reference, derived from public patent data, enterprise disclosed materials and exclusive first-hand industrial oral information cross-verification, independent of short-term clinical rhythm fluctuations and secondary market sentiment disturbances. In case of extreme macro variables including global semiconductor supply chain decoupling, medical device regulatory policy revision, ETSI/ISO international standard iteration, unforeseen biological compatibility black swan events, deviations may exist between actual industrial valuation trends and research deduction conclusions. All institutional and individual investors shall conduct independent risk assessment and investment decision-making, and bear all corresponding investment risks independently.

中文：本研究聚焦脑机接口产业终局价值量化推演与半导体技术模型构建，遵循半导体产业经济学与长周期前沿技术研判范式，不构成任何个股推介、交易指导及投资决策依据。全文定价逻辑、产业对标结论、技术路线预测仅用于学术研究与产业参考，基于公开专利数据、企业披露材料、独家一手产业口述信息交叉校验得出，独立于短期临床节奏波动与二级市场情绪扰动。若出现全球半导体供应链脱钩、医疗器械监管政策修订、ETSI/ISO 国际标准迭代、不可预判生物相容性黑天鹅事件等极端宏观变量，产业估值走势与研究推演结论或存在偏差。所有机构及个人投资者需自主开展风险评估与投资决策，独立承担全部对应投资风险。

TITLE INFORMATION｜扉页信息

Co-Chief Researcher｜联席首席：Icall Lee (Dean of Zha Academy, Founder of New Quality Productivity Endgame Pricing System)｜Icall Lee（渣学院院长李俊・新质生产力终局定价体系创始人）Global Paradigm Architect｜顶层范式架构：Yang Qing (Global Frontier Medical Semiconductor Chief Analyst, Founder of BCI Semiconductor Dimensional Pricing Paradigm, the world’s first scholar to separate BCI from medical narrative and build wafer-process anchor valuation system)｜阳啨（全球前沿医疗半导体首席分析师，BCI 半导体维度定价范式缔造者，全球首位将 BCI 剥离医疗叙事、搭建晶圆制程锚定估值体系的学术研发人）Exclusive Industrial Source Coordinator｜独家产业信源统筹：Xiang Zhenfei (Chairman & President of Weizhi Medical, core dialogue object of Zha Academy exclusive oral industrial history system)｜向振飞（微智医疗董事长兼总裁，渣学院独家产业口述史体系核心交流对象）Research Team｜参与团队：Qin Xiangyu, Lin Suhu, Li Shuangquan｜秦翔宇、林苏沪、李双全Research Oral Source Database｜研究口述信源库：Exclusive Zha Academy Industry Dialogue Archive (2025-2026 Multi-Round One-on-One Exchange Records between Icall Lee & Xiang Zhenfei, marked as [Oral・Xiang-Li] for distinction from public materials)｜渣学院专属产业对话档案库（2025-2026 李俊 × 向振飞多轮一对一交流实录，标注【口述・向李】以区分公开材料）Report Date｜报告日期：July 01, 2026｜2026 年 07 月 01 日Global Exclusive Research Framework｜全球独创顶配研究体系：Yang Qing BCI Semiconductor Dimensional Pricing Paradigm (Channel Moore’s Law・Wafer Process Anchor・Medical Payment Closed-Loop・Global Standard Sovereignty) + Technology-Capital-Policy Triangular Verification Framework + Channel-Process Node Global Mapping Model + Patent Entropy Quantitative Barrier Rating System + Three-Stage Cognitive Arbitrage Capital Pricing System

中文：阳啨 BCI 半导体维度定价范式（通道摩尔定律・晶圆制程锚定・医疗支付闭环・全球标准主权）+「技术 - 资本 - 政策」三角验证框架 + 通道 - 制程节点全球映射模型 + 专利熵量化壁垒评级体系 + 三阶段认知套利资本定价体系Global Investment Rating｜全球投资评级（前沿硬科技产业研究评级）：Optimistic (Frontier Bio-Semiconductor Long-Term Layout)｜Provides forward-looking industrial layout references completely different from traditional medical short-term PEG rating system中文：乐观布局（前沿生物半导体产业长期顶配配置参考）｜区别于传统医药短期 PEG 评级体系，提供前瞻性、长周期、跨行业体系化产业布局学术参考Target Audience｜适配受众：Global Sovereign Wealth Innovation Funds, Offshore Biotech Green Fund of Funds, Cross-Border Medical Pension Allocation Capital, Ultra-Long-Term Insurance Equity Capital, Top-Tier Cross-Border Hard-Tech Hedge Funds, Primary & Secondary Market Linked Medical Industrial Capital, Global Offshore Pricing Research Institutions for Bio-Semiconductor Frontier Tracks

中文：全球主权财富创新基金、离岸生物科技绿色母基金、跨国医疗养老金配置资金、保险超长周期权益配置资金、头部跨境硬科技对冲基金、一二级联动医疗产业资本、全球生物半导体前沿赛道离岸定价研究机构

VALIDITY STATEMENT｜效力声明

中文：本白皮书为聚焦全球脑机接口产业、首创半导体重定价逻辑的原创性学术底稿，全文中英双语逻辑框架、通道制程测算口径、离岸估值校准标准、专利熵评级体系高度适配、逻辑统一。若中英文释义存在分歧，以中文版本为唯一权威判定标准。本报告全套定价体系、量化评级模型、认知套利锚定逻辑均为原创学术框架，彻底颠覆全球主流券商老旧医疗器械研究范式，专为生物半导体离岸定价与超长周期前沿科技资产配置场景构建，具备独立、完整、排他的学术研究价值。全文标注【口述・向李】内容为李俊与微智医疗向振飞一对一深度交流一手产业情报，仅作产业推演参考，不等同企业已量产、已流片、已临床落地成果，所有标的产业数据以企业公开披露文件为最终核验依据。

English：This whitepaper is the world’s first exclusive endgame pricing manuscript targeting global BCI frontier tracks with original semiconductor re-pricing logic. The bilingual logical framework, channel-process calculation criteria, offshore valuation calibration rules and patent entropy rating standards are fully consistent. The Chinese version shall prevail as the sole global authoritative standard in case of any interpretation divergence. The entire pricing system, quantitative rating models and cognitive arbitrage anchoring logic in this report are original academic frameworks, establishing a new-generation cross-industry research dimension that completely subverts and dominates all outdated medical device paradigms of global mainstream brokerages. It is exclusively constructed for offshore pricing of bio-semiconductor assets and ultra-long-term frontier technology asset allocation scenarios, possessing independent, complete and exclusive academic research value. All contents marked [Oral·Xiang-Li] are first-hand industrial intelligence from one-on-one in-depth exchanges between Icall Lee and Xiang Zhenfei of Weizhi Medical, only used for industrial deduction reference, not equivalent to mass-produced, taped-out or clinically verified enterprise products; all industrial data of target companies shall be finally verified based on official disclosed documents.

CORE RESEARCH FRAMEWORK｜核心研究体系（GLOBAL TOP-TIER PARADIGM）

Chinese Top-Tier Paradigm Interpretation (Dimensional Transcendence Over Traditional Medical Brokerage System)｜中文顶配范式说明（维度碾压传统医药券商范式体系）

全球券商主导的医疗器械、创新药研究框架，根植于医药临床赛道底层逻辑，存在天然跨产业认知缺陷，完全无法适配 BCI 生物半导体的产业运行规律，形成不可逾越的代际研究鸿沟。传统医药投研体系三大核心认知局限：

其一，估值锚点单一化，所有医疗资产统一采用 PE/PEG、患者池、适应症数量作为定价核心变量，默认医疗产业成长依靠临床拓展，完全忽略 BCI 核心成长驱动是半导体通道摩尔定律、晶圆制程迭代、先进封装良率提升，错把半导体硬件赛道归为医药耗材赛道，造成全行业持续性估值折价；

其二，壁垒定价浅层化，传统医药研究仅量化临床数据、审批进度、专利药保护期等软性医疗壁垒，无法拆解 BCI 全链路半导体壁垒：柔性电极材料、定制 ASIC 芯片、低噪声 AFE、高精度 ADC、植入级 SiP/CoWoS 封装、无线 THz 通信 IP，不能量化随制程迭代持续增厚的硬件复利壁垒；

其三，全球竞争格局线性化，海外机构单一对标企业临床样本量判断行业位次，割裂美、欧、中三方差异化竞争战略 —— 美国主攻半导体通道参数军备竞赛、欧洲抢占国际通信标准主权、中国走微创模组 + 医保支付不对称超车路线，缺失分赛道、分维度辩证终局推演能力，无法预判长期全球定价权转移趋势。

本研究彻底重构适配 BCI 生物半导体赛道的专属产业经济学研判范式，推翻券商基于医疗器械搭建的老旧估值体系，落地三大顶配原创投研框架，锚定半导体通道摩尔复利、晶圆制程迭代上限、国际标准话语权、微创差异化壁垒、国内唯一全链路支付闭环五大核心底层产业逻辑，构建「制程迭代定义通道天花板、通道密度锁定临床康复价值、标准主权构筑全球准入壁垒、医保闭环兑现商业化收益、认知套利修复全市场估值错配」的闭环终局定价逻辑。这是当前全球唯一同时覆盖美欧中三方 BCI 产业、打通半导体硬件 + 医疗临床双维度、适配离岸长线资金配置需求的顶级离岸研究体系，真正实现从「临床行情表面解读」到「半导体产业底层机理终局研判」的维度升级。

三大全球独创核心量化工具（代际超越全球医药券商全部现有模型）

阳啨 BCI 半导体四维定价范式（全球独家）：针对性破解传统医药 PEG 模型短期临床预判的结构性缺陷，以侵入式、微创视觉、非侵入式三大 BCI 细分赛道为研究样本，从晶圆制程迭代速率、单芯片最大通道容量、植入封装良率、医疗支付闭环渗透率四大核心维度，锁定 5-10 年长周期估值中枢，规避传统研报仅看适应症线性外推的系统性偏差，实现生物半导体资产长期终局价值的精准量化锚定。
「技术 - 资本 - 政策」三角验证风控体系（代际超越券商单一临床风控体系，形成降维风控壁垒）：在海外医药机构通用临床审批、临床安全校验基础上，叠加适配生物半导体赛道三大终局风险红线 —— 半导体供应链断供风险、国际标准 SEP 专利壁垒风险、生物相容性长期安全衰减风险，将传统「短期临床安全筛查」浅层逻辑，升维至「十年产业永续迭代、全球商业化落地能力核验」的终局研判标准，精准适配全球分层 BCI 企业的筛选与差异化风险定价体系。
BCI 通道 - 制程节点全球映射模型（全球首创）：构建制程节点与单芯片承载通道数一一对应的量化对标框架，覆盖 65nm 至 3nm 全制程演进路线，精准测算每一代工艺迭代带来的通道密度提升、单通道功耗下降、BOM 成本下行空间，直接锚定 BCI 企业长期成长天花板；配套专利熵量化壁垒评级体系、三阶段认知套利资本定价体系，完整甄别题材炒作医疗壳公司与具备全栈半导体自研能力的硬核 BCI 资产，搭建分层差异化离岸价值甄别体系。

English Top-Tier Paradigm Statement (Dimensional Transcendence Over Traditional Medical Brokerage Outdated System)

The medical device and innovative drug research frameworks dominated by global brokerages are structurally obsolete with fundamental industrial logic defects rooted in clinical pharmaceutical tracks, inherently incompatible with the operational laws of BCI bio-semiconductor industries, forming an insurmountable generational research gap. The traditional pharmaceutical investment research system has three core cognitive limitations: First, single valuation anchor. All medical assets uniformly adopt PE/PEG, patient pool and indication quantity as core pricing variables, assuming medical industry growth relies on clinical expansion, completely ignoring that the core growth drivers of BCI are semiconductor channel Moore’s Law, wafer process iteration and advanced packaging yield improvement, misclassifying semiconductor hardware tracks as medical consumable tracks and leading to persistent valuation discounts across the whole industry. Second, superficial barrier pricing logic. Traditional pharmaceutical research only quantifies soft medical barriers such as clinical data, approval progress and patent protection term, failing to disassemble the full-link semiconductor barriers of BCI including flexible electrode materials, customized ASIC chips, low-noise AFE, high-precision ADC, implant-grade SiP/CoWoS packaging and wireless THz communication IP, incapable of quantifying hardware compound barriers that continuously thicken with process iteration. Third, linear global competition pattern cognition. Overseas institutions judge industrial rankings solely based on enterprise clinical sample size, separating the differentiated competitive strategies of US, Europe and China — the US focuses on semiconductor channel parameter arms race, Europe seizes international communication standard sovereignty, China adopts asymmetric overtaking route of minimally invasive modules + medical insurance payment, lacking differentiated long-term endgame deduction capability by track and dimension, unable to predict the long-term transfer trend of global pricing power.

This research thoroughly reshapes the exclusive industrial economic paradigm adapted to BCI bio-semiconductor tracks and eliminates the outdated valuation logic of global pharmaceutical brokerages. It establishes three world-class original investment research systems based on five core underlying industrial logics: semiconductor channel compound appreciation, wafer process iteration ceiling, international standard discourse power, differentiated minimally invasive barriers and China’s exclusive full-link payment closed-loop. A full-link closed-loop pricing logic is formed: technological iteration defines channel ceiling, channel density locks clinical rehabilitation value, standard sovereignty constructs global access barriers, medical insurance closed-loop realizes commercial income and cognitive arbitrage corrects industrial valuation mispricing. It serves as the world’s exclusive top-tier offshore research framework covering US-EU-China BCI industries, integrating semiconductor hardware and medical clinical dimensions, and matching the allocation demands of offshore long-cycle capital, realizing a fundamental upgrade from superficial clinical market interpretation to underlying bio-semiconductor industrial mechanism endgame judgment.

CHAPTER 1 产业范式迭代：全球 BCI 认知三层误区与半导体本体独占性禀赋

1.1 全球资本市场 BCI 估值范式三层结构性认知误区

中文：纵观全球脑机接口产业资本定价格局，全球机构对 BCI 产业的研判历经三轮错误叙事迭代，传统医药估值逻辑、消费电子成长逻辑、AI 应用叙事全部失效，形成不可逆的三层结构性认知偏差，持续压制行业整体估值中枢。第一层：2016-2019 消费电子泡沫叙事，市场将 BCI 归类为意念控制消费终端赛道，核心逻辑为 C 端消费放量，完全无视植入式 BCI 高壁垒半导体硬件属性，泡沫破裂后长线资本集体离场；第二层：2019-2023 医疗器械叙事，全市场统一使用创新药 / 高值耗材 PEG 估值框架，锚定适应症数量、临床入组人数测算长期空间，核心缺陷是完全剥离芯片、封装、晶圆制程等硬件成长变量，低估通道迭代带来的十倍级空间增量；第三层：2023-2026 AI + 医疗应用叙事，市场将 BCI 定义为 AI 算法下游配套场景，估值锚定算法迭代，忽视硬件信号链才是产业核心瓶颈，算法仅为配套辅助环节。

本白皮书落地全新第四层终极研判范式：BCI 本质是第三代生物半导体模组，医疗临床仅为首个商业化支付场景，而非产业技术本体，全链路信号链由电极材料、CMOS 模拟前端、高精度 ADC、嵌入式 SoC、THz 无线通信、AI 量化固件、先进封装七大半导体模块构成，无纯医疗技术变量，制程、良率、通道密度、单通道功耗才是唯一长期估值锚，彻底修正全球机构三层历史认知偏差，搭建全新离岸定价体系。

English：From the perspective of global capital pricing pattern of BCI industry, global institutions’ research and judgment on BCI industry have gone through three rounds of wrong narrative iteration. Traditional pharmaceutical valuation logic, consumer electronics growth logic and AI application narrative all fail, forming irreversible three-layer structural cognitive deviation that continuously suppress the overall industrial valuation center. The first layer: 2016-2019 consumer electronics bubble narrative. The market classified BCI as a consumer terminal track controlled by mind, with core logic of C-end consumption volume expansion, completely ignoring the high-barrier semiconductor hardware attribute of implantable BCI. Long-cycle capital withdrew collectively after the bubble burst. The second layer: 2019-2023 medical device narrative. The whole market uniformly adopted the PEG valuation framework of innovative drugs/high-value consumables, measuring long-term space based on indication quantity and clinical enrollment number. The core defect is completely stripping hardware growth variables such as chips, packaging and wafer processes, underestimating the tenfold space increment brought by channel iteration. The third layer: 2023-2026 AI+medical application narrative. The market defined BCI as a downstream supporting scenario of AI algorithms, with valuation anchored on algorithm iteration, ignoring that hardware signal chain is the core industrial bottleneck and algorithms are only supporting auxiliary links.

This whitepaper launches a brand-new fourth-layer ultimate research paradigm: BCI is essentially the third-generation bio-semiconductor module, medical clinic is only the first commercial payment scenario rather than industrial technical ontology. The full-link signal chain consists of seven semiconductor modules including electrode materials, CMOS analog front-end, high-precision ADC, embedded SoC, THz wireless communication, AI quantitative firmware and advanced packaging, without pure medical technical variables. Process, yield, channel density and single-channel power consumption are the only long-term valuation anchors, completely correcting three layers of historical cognitive deviation of global institutions and building a new offshore pricing system.

1.2 BCI 生物半导体五大独占性终局底层禀赋

中文：基于臻研社专利熵量化体系、中美欧三方产业对标体系交叉核验，全球 BCI 赛道的核心长期价值不来自临床数据、短期营收，而是五大半导体独占底层壁垒构筑的、不可复刻的产业终局格局，彻底脱离传统医药内卷竞争体系。第一，全链路半导体自研准入壁垒：完整 BCI 系统覆盖柔性半导体电极、定制 ASIC、低噪声 AFE、12-16bit SAR ADC、植入级无线 SoC、TSV 晶圆级封装六大芯片制造环节，整套硬件链路无通用标准化芯片可直接采购，必须企业自主完成流片、光刻、封装全流程开发，单项目研发投入十亿级、研发周期 5-8 年，中小资本、跨界药企无法短期突破，天然形成寡头垄断格局；第二，通道摩尔定律低折旧复利成长壁垒：区别于医药耗材适应症天花板固定的线性成长逻辑，BCI 通道数量遵循类摩尔定律，每 24-36 个月通道容量翻倍，同步带动临床康复效果阶梯式提升，技术迭代遵循「制程升级 - 通道扩容 - 临床价值增厚」增值逻辑，芯片硬件资产不会随临床迭代贬值，越深耕制程、积累封装工艺，壁垒持续复利增厚，颠覆医药资产折旧衰减规律；第三，差异化区域战略竞争格局壁垒：美、欧、中三方形成完全错位竞争赛道，无全域同质化内卷。美国垄断高端万级通道半导体工程能力，但缺失医保支付闭环；欧洲掌控全球体域网络通信标准制定权，但无成熟落地终端产品；中国独家打通「监管审批 - 手术落地 - 医保编码 - 商业化盈利」全链路支付闭环，微创硬膜外路线规避皮层穿刺生物相容性风险，形成本土不对称竞争壁垒，三方资源、赛道、目标市场高度分割，各自独享本土增量红利；第四，跨行业长周期刚需壁垒：BCI 同时覆盖重度致残疾病医疗刚需、人机交互下一代消费电子、脑科学国家安全三大永续刚需赛道，需求不受单一医药政策、消费周期扰动，兼具医疗产业防御属性与半导体科技成长弹性，极致跨周期稳健增值；第五，十年级工艺沉淀重资产壁垒：先进植入封装、柔性生物兼容半导体材料、颅内无线低功耗供能体系均需要十年以上工程数据、临床样本积累，无法依靠短期资本烧钱、外购成熟技术实现弯道超车，锁死行业长期竞争终局，构筑超长周期硬件护城河。

English：Cross-verified by Zhenyan Society’s patent entropy quantitative system and US-EU-China three-party industrial benchmarking system, the core long-term value of global BCI tracks does not come from clinical data or short-term revenue, but from an irreplicable industrial endgame pattern built by five exclusive underlying semiconductor barriers, fundamentally breaking away from the traditional involution competition system of pharmaceutical industry. First, full-link self-developed semiconductor access barrier. A complete BCI system covers six chip manufacturing links including flexible semiconductor electrodes, customized ASIC, low-noise AFE, 12-16bit SAR ADC, implant-grade wireless SoC and TSV wafer-level packaging. No general standardized chips can be directly purchased for the whole hardware link, and enterprises must independently complete the full-process development of tape-out, lithography and packaging. The R&D investment of a single project reaches billions with a 5-8 year R&D cycle. Small and medium capital and cross-border pharmaceutical enterprises cannot achieve short-term breakthrough, forming a natural oligopolistic pattern. Second, low-obsolescence compound growth barrier of channel Moore’s Law. Different from the linear growth logic of fixed indication ceiling of medical consumables, the number of BCI channels follows quasi-Moore’s Law, with channel capacity doubling every 24-36 months, driving stepped improvement of clinical rehabilitation effects simultaneously. Technical iteration follows the value-added logic of "process upgrading - channel expansion - increased clinical value". Chip hardware assets will not depreciate with clinical iteration. The deeper enterprises engage in process development and accumulate packaging technology, the thicker barriers compound continuously, subverting the depreciation attenuation law of pharmaceutical assets. Third, differentiated regional strategic competition pattern barrier. The US, Europe and China form completely staggered competitive tracks without full-domain homogeneous involution. The US monopolizes the engineering capability of high-end ten-thousand-level channel semiconductors but lacks a closed-loop medical insurance payment system; Europe holds the discourse power of global body area network communication standard formulation but has no mature landed terminal products; China exclusively opens up the full-link payment closed-loop of "regulatory approval - surgical implementation - medical insurance coding - commercial profit", and the minimally invasive epidural route avoids the biocompatibility risk of cortical puncture, forming an asymmetric local competition barrier. Resources, tracks and target markets of the three parties are highly divided, each exclusively enjoying local incremental dividends. Fourth, cross-industry long-cycle rigid demand barrier. BCI simultaneously covers three sustainable rigid demand tracks including medical treatment for severe disabling diseases, next-generation consumer electronics of human-computer interaction and national security of brain science. Demand is not disturbed by single pharmaceutical policies or consumption cycles, with both defensive attributes of medical industry and growth elasticity of semiconductor technology, achieving extremely stable cross-cycle value appreciation. Fifth, ten-year-level process accumulation heavy-asset barrier. Advanced implant packaging, flexible biocompatible semiconductor materials and intracranial wireless low-power energy supply systems all require more than ten years of engineering data and clinical sample accumulation. Overtaking through short-term capital investment or purchasing mature technology is impossible, permanently locking the long-term industrial competition endgame and building an ultra-long-term hardware moat.

1.3 全球 BCI 赛道三方梯队终局分层评级（半导体四维五星 HALO 适配体系）

中文：依托专利熵量化壁垒评级体系、通道 - 制程映射模型、三角验证风控体系，本文对美国、欧洲、中国三大区域核心 BCI 赛道开展分层终局量化评级，构建「五星万级通道底层资产、四星半千通道高成长中坚、四星微创医保稳健防御、前瞻消费级远期跃迁」完整产业梯队，覆盖短期商业化兑现、中期制程迭代、十年长周期离岸配置全维度价值。1、五星万通道半导体底层资产（战略底仓・美国赛道）：侵入式高通道 BCI（Neuralink、Paradromics）。赛道四维半导体定价因子满分，自研 VLSI 全栈 ASIC、65536 通道极限承载能力、EUV 先进封装工艺、自动植入机器人工程壁垒拉满，通道摩尔定律迭代空间无天花板，全球半导体硬件能力绝对垄断；短板为无 FDA 商用 PMA 审批、无医保支付闭环，短期无规模化营收，适配超长周期主权创新基金、一级市场长线产业资本底仓配置。2、四星半千通道高成长中坚赛道（业绩中坚・中美分赛道）：美国半侵入 BCI（Precision）、中国视觉微创 BCI（微智医疗 IMIE）。赛道重半导体壁垒稳固，通道容量 256-1024 级，国产替代 / 本土商业化空间广阔；美国标的具备成熟商用医疗器械审批通道，中国微智医疗独家打通湖南医保支付闭环，微创贴附路线生物相容性优势突出，兼具长线硬件防御属性与中短期估值弹性，是离岸中线产业资本、跨境主题基金核心配置中坚。核心产业主体：微智医疗（256 通道临床落地，512 通道研发完成，1024-2048 通道【口述・向李】技术储备）、Precision。3、四星稳健防御赛道（跨周期对冲・中国特色赛道）：非侵入康复 BCI（强脑科技 BrainCo）。刚需康复医疗场景稳定、无颅内植入安全风险，临床审批节奏平缓，现金流稳健，完全对冲高通道侵入式 BCI 临床审批、生物相容性波动风险，适配保险固收 + 权益、稳健跨境对冲资金作为组合防御底仓。4、前瞻远期跃迁赛道（远期范式溢价・全球同步布局）：消费级 BCI、视网膜 AMD 全适应症拓展、3nm 万通道下一代生物半导体。当前处于产业早期培育阶段，短期业绩兑现缓慢，但长期不受现有临床、通道竞争格局约束，具备从医疗专用设备跨越至全民消费电子的范式升级天花板，适配主权基金创新仓位、一级市场前瞻科技资本预埋布局。核心产业方向：微智医疗 AMD 适应症拓展、Apple/Meta 消费级 BCI 原型、3nm CoWoS 封装万通道 BCI 研发。

English：Based on the patent entropy quantitative barrier rating system, channel-process mapping model and triangular verification risk control system, this paper conducts hierarchical endgame quantitative rating on core BCI tracks in three major regions of the US, Europe and China, forming a complete industrial echelon of five-star ten-thousand-channel bottom assets, four-and-a-half star thousand-channel high-growth backbone, four-star minimally invasive medical insurance stable defense and forward-looking consumer-grade long-term leapfrog, covering full-dimensional value including short-term commercialization delivery, medium-term process iteration and ten-year ultra-long-cycle offshore allocation.

Five-star ten-thousand-channel semiconductor bottom assets (strategic bottom position · US tracks): Invasive high-channel BCI (Neuralink, Paradromics). The track achieves full scores in four-dimensional semiconductor pricing factors, with full-stack self-developed VLSI ASIC, extreme carrying capacity of 65536 channels, EUV advanced packaging process and full engineering barriers of automatic implantation robots. The iteration space of channel Moore’s Law has no ceiling, with absolute monopoly of global semiconductor hardware capability. The shortcoming is no FDA commercial PMA approval and no closed-loop medical insurance payment, resulting in no large-scale short-term revenue, suitable for bottom-position allocation of ultra-long-cycle sovereign innovation funds and primary market long-cycle industrial capital.
Four-and-a-half star thousand-channel high-growth backbone tracks (performance backbone · segmented tracks of China and US): US semi-invasive BCI (Precision), Chinese visual minimally invasive BCI (Weizhi Medical IMIE). The track has solid heavy semiconductor barriers with channel capacity of 256-1024 levels, sufficient space for domestic substitution/local commercialization. US targets have mature commercial medical device approval channels, while China’s Weizhi Medical exclusively opens up the closed-loop Hunan medical insurance payment system, and the minimally invasive attachment route highlights biocompatibility advantages, with both long-term hardware defensive attributes and medium-short-term valuation elasticity. It is the core allocation backbone of offshore medium-term industrial capital and cross-border thematic funds. Core industrial entities: Weizhi Medical (256 channels clinically implemented, 512 channels R&D completed, 1024-2048 channels technical reserve [Oral·Xiang-Li]), Precision.
Four-star stable defense tracks (cross-cycle hedging · China characteristic tracks): Non-invasive rehabilitation BCI (BrainCo). Stable rigid-demand rehabilitation medical scenarios, no intracranial implantation safety risks, smooth clinical approval rhythm and steady cash flow, fully hedging clinical approval and biocompatibility fluctuation risks of high-channel invasive BCI, suitable for insurance fixed income + equity and stable cross-border hedging capital as portfolio defense bottom positions.
Forward-looking long-term leapfrog tracks (long-term paradigm premium · global synchronous layout): Consumer-grade BCI, full-indication expansion of retinal AMD, next-generation bio-semiconductors with ten-thousand channels under 3nm process. Currently in the early industrial cultivation stage with slow short-term performance delivery, but free from constraints of existing clinical and channel competition patterns in the long run, possessing an industrial upgrading ceiling from special medical equipment to national consumer electronics, suitable for forward layout of sovereign fund innovation positions and primary market forward technology capital. Core industrial directions: AMD indication expansion of Weizhi Medical, Apple/Meta consumer-grade BCI prototype, R&D of ten-thousand-channel BCI with 3nm CoWoS packaging.

CHAPTER 2 范式错配：传统医药估值体系全面失效与 BCI 跨境认知价值洼地

2.1 全球券商传统医疗定价范式四大核心底层缺陷

中文：当前全球券商通用医疗定价体系核心弊端，是将创新药、高值耗材的临床线性估值逻辑，生硬套用于 BCI 生物半导体重资产赛道，底层产业逻辑完全错配，形成持续性、全行业系统性估值折价。其一，产业成长逻辑错配：医药资产成长上限由适应症患者池锁定，属于存量市场博弈；BCI 成长上限由晶圆制程工艺、单芯片通道容量决定，通道扩容持续打开十倍级增量市场，机构用存量医药空间模型测算增量半导体赛道，长期严重低估产业天花板；其二，资产折旧逻辑错配：传统医疗模型默认设备、耗材随临床迭代价值衰减，而 BCI 半导体遵循制程积淀增值逻辑，芯片设计、封装工艺、电极材料工艺积累越久，硬件壁垒越高、单位通道成本持续下行，反向复利增值，传统模型完全无法量化该特质溢价；其三，全球竞争格局逻辑错配：通用医药估值模型默认全球企业同质化临床竞争，未纳入美国硬件军备竞赛、欧洲标准主权博弈、中国微创支付闭环三方差异化战略因子，缺失标准专利 SEP、本土医保垄断两大长期溢价定价维度；其四，资本催化逻辑错配：医药体系仅将 NMPA/FDA 审批、临床终点数据定义为核心估值催化，忽视晶圆厂制程路线落地、先进封装良率突破、THz 无线通信 SEP 专利卡位、医保全省复制四大半导体维度核心重估催化，持续错过产业范式级上涨窗口。

English：The core drawback of the general medical pricing system adopted by global brokerages is the rigid application of the linear clinical valuation logic of innovative drugs and high-value consumables to the heavy-asset track of BCI bio-semiconductors, resulting in complete mismatch of underlying industrial logic and persistent systematic valuation discounts across the whole industry. First, industrial growth logic mismatch. The growth ceiling of medical assets is locked by indication patient pool, belonging to stock market game; the growth ceiling of BCI is determined by wafer process technology and single-chip channel capacity, and channel expansion continuously opens tenfold incremental markets. Institutions measure incremental semiconductor tracks with stock medical space models, seriously underestimating the industrial ceiling in the long run. Second, asset depreciation logic mismatch. Traditional medical models assume that the value of equipment and consumables attenuates with clinical iteration, while BCI semiconductors follow the logic of process accumulation and appreciation. The longer chip design, packaging technology and electrode material technology accumulate, the higher hardware barriers become and the unit channel cost continues to decline, generating reverse compound appreciation. Traditional models cannot quantify this characteristic premium at all. Third, global competition pattern logic mismatch. General medical valuation models assume homogeneous clinical competition among global enterprises, excluding differentiated strategic factors of three parties including US hardware arms race, European standard sovereignty game and China’s minimally invasive payment closed-loop, completely lacking two long-term premium pricing dimensions of standard patent SEP and local medical insurance monopoly. Fourth, capital catalyst logic mismatch. The medical system only defines NMPA/FDA approval and clinical endpoint data as core valuation catalysts, ignoring four core revaluation catalysts of semiconductor dimension including wafer factory process roadmap implementation, advanced packaging yield breakthrough, THz wireless communication SEP patent carding and provincial replication of medical insurance, continuously missing paradigm-level industrial upward windows.

2.2 全球 BCI 五维度认知套利：全行业确定性估值错配修复空间

中文：基于本研究原创通道 - 制程映射模型、三阶段认知套利定价锚量化测算，全球 BCI 生物半导体资产当前存在高确定性、可持续的跨境估值错配套利空间。相较于传统创新药、医疗耗材、消费电子标的，BCI 资产具备五重折价修复逻辑共振支撑：一是成长天花板折价修复，机构仍用医药患者池测算行业空间，未纳入晶圆制程通道扩容带来的十倍增量，存在系统性成长上限误判折价；二是半导体特质折价修复，低折旧硬件复利、通道摩尔增长的独特半导体属性未被医药估值模型纳入定价，形成赛道特质估值折价；三是全球格局折价修复，美欧中三方差异化垄断战略、欧洲 SEP 标准税、中国医保闭环壁垒未被通用估值模型定价，存在显著格局垄断价值折价；四是技术催化折价修复，中芯 / 台积电制程迭代、先进封装良率突破等硬件核心驱动未被短期临床行情定价，存在半导体技术终局折价；五是离岸认知折价修复，全球长线主权、绿色医疗资本尚未完成「BCI = 生物半导体」的范式认知切换，仍沿用医药研究员定价框架，存在跨行业认知定价折价。五重折价机制同步共振，构筑 BCI 硬核生物半导体资产中长期维度确定性最强的估值回填与范式重估上行空间。

English：Calculated based on the original channel-process mapping model and three-stage cognitive arbitrage pricing anchor proposed by this research, global BCI bio-semiconductor assets currently have highly certain and sustainable cross-border valuation mismatch arbitrage space. Compared with traditional innovative drugs, medical consumables and consumer electronics targets, BCI assets are supported by the resonance of five-fold discount repair logic. First, growth ceiling discount repair. Institutions still measure industrial space with medical patient pools, failing to include tenfold increments brought by wafer process channel expansion, resulting in systematic misjudgment discount of growth upper limit. Second, semiconductor characteristic discount repair. Unique semiconductor attributes including low-obsolescence hardware compound interest and channel Moore growth are not incorporated into pricing by medical valuation models, forming track characteristic valuation discount. Third, global pattern discount repair. Differentiated monopoly strategies of US, Europe and China, European SEP standard tax and China’s medical insurance closed-loop barriers are not priced by general valuation models, leading to significant pattern monopoly value discount. Fourth, technical catalyst discount repair. Core hardware drivers such as SMIC/TSMC process iteration and advanced packaging yield breakthrough are not priced by short-term clinical market trends, resulting in semiconductor technology endgame discount. Fifth, offshore cognitive discount repair. Global long-cycle sovereign and green medical capital have not completed the paradigm cognitive switch of "BCI = bio-semiconductor", still adopting the pricing framework of medical researchers, resulting in cross-industry cognitive pricing discount. The resonance of the five-fold discount mechanism builds the most certain medium and long-term valuation backfilling and paradigm revaluation upward space for BCI hardcore bio-semiconductor assets.

CHAPTER 3 BCI 半导体终局定价：五大永续硬件因子与三重递进价值重估路径

3.1 BCI 生物半导体五大永续低折旧定价核心因子

中文：基于臻研社通道 - 制程 HALO 终局定价模型底层产业经济学逻辑，全球 BCI 资产长期溢价根源并非临床数据、短期业绩增速、医疗题材热点，而是五大不可复刻的永续半导体底层因子，是支撑资产穿越十年制程迭代、全球资本周期、宏观医疗政策波动的终极价值基石。

第一，全栈自研半导体重资产准入永续溢价（硬件垄断）：完整 BCI 信号链自研周期 5-8 年、单链条研发投入十亿级，柔性电极、定制 ASIC、植入封装均为国家管制类生物半导体硬件，建设周期长、光刻流片资源排他、高端设备供给独占，市场化医药资本无法短期突破、跨界企业无法复刻、区域竞争对手无法追赶，形成永久性硬件产业准入垄断，锁定长期高毛利率与通道稀缺溢价；

第二，通道摩尔定律低迭代复利溢价（成长垄断）：区别于医药耗材适应症天花板固定逻辑，BCI 通道容量随晶圆制程升级持续翻倍，工艺积淀不存在技术淘汰贬值，芯片、封装、电极工程经验随项目落地持续增厚，每一代制程升级同步打开全新临床适应症、消费电子应用市场，产业成长永续复利增值，彻底摆脱传统医疗资产折旧衰减宿命；

第三，全球差异化战略刚需无周期溢价（需求垄断）：美欧中三方赛道分别锚定高端脑科学国防安全、全球通信标准基建、国内重度致残医疗民生刚需三大国家级永续需求，分区域市场完全隔离，不受单一消费下行、医药集采周期扰动，极致跨周期稳定成长；

第四，区域独家商业化闭环溢价（格局垄断）：美国独占高端万通道硬件研发资源但无医保支付；欧洲独占国际通信 SEP 标准定价权但无终端产品；中国独家打通「审批 - 手术 - 医保 - 盈利」完整商业化链路，国内无同能级竞争企业，区域市场份额持续集中，永续兑现本土商业化垄断溢价；

第五，十年级工艺沉淀不可逾越壁垒溢价（时间垄断）：植入级生物兼容封装、颅内低功耗无线供能、微米级柔性电极阵列均需要十年以上临床与工程数据积累，资本无法依靠短期并购、外购技术完成追赶，锁死未来十年全球产业竞争终局，构筑超长周期硬件护城河。

English：Based on the underlying industrial economic logic of Zhenyan Society’s channel-process HALO endgame pricing model, the long-term premium source of global BCI assets does not lie in clinical data, short-term performance growth rate or medical speculative hot topics, but in five irreplicable sustainable underlying semiconductor factors, serving as the ultimate value cornerstone spanning ten-year process iteration, global capital cycles and macro medical policy fluctuations.First, sustainable premium of full-stack self-developed semiconductor heavy-asset access (hardware monopoly). The self-development cycle of a complete BCI signal chain lasts 5-8 years with billions of R&D investment for a single chain. Flexible electrodes, customized ASIC and implant packaging are all state-controlled bio-semiconductor hardware with long construction cycles, exclusive lithography tape-out resources and monopolized high-end equipment supply. Market-oriented medical capital cannot achieve short-term breakthrough, cross-border enterprises cannot replicate, and regional competitors cannot catch up, forming permanent hardware industrial access monopoly and locking long-term high gross profit margin and channel scarcity premium.Second, low-obsolescence technological compound premium of channel Moore’s Law (growth monopoly). Different from the logic of fixed indication ceiling of medical consumables, BCI channel capacity doubles continuously with the upgrading of wafer processes, and process accumulation has no technological elimination and depreciation. Engineering experience of chips, packaging and electrodes accumulates continuously with project implementation. Each generation of process upgrading simultaneously opens new clinical indications and consumer electronics application markets, presenting sustainable compound industrial growth and completely breaking away from the inherent depreciation attenuation fate of traditional medical assets.Third, acyclical premium of differentiated global strategic rigid demand (demand monopoly). Tracks of the US, Europe and China anchor three national-level sustainable demands including national defense security of high-end brain science, global communication standard infrastructure and people’s livelihood medical treatment for severe domestic disabilities respectively. Regional markets are completely isolated, free from disturbances of single consumption downturn and medical centralized procurement cycles, with extreme cross-cycle stable growth.Fourth, exclusive regional commercial closed-loop premium (pattern monopoly). The US monopolizes high-end ten-thousand-channel hardware R&D resources but lacks medical insurance payment; Europe holds the pricing power of international communication SEP standards but has no terminal products; China exclusively opens up the complete commercial link of "approval - surgery - medical insurance - profit", with no peer competitive enterprises in China. Regional market shares continue to concentrate, sustaining the delivery of local commercial monopoly premium.Fifth, insurmountable barrier premium of ten-year-level process accumulation (time monopoly). Implant-grade biocompatible packaging, intracranial low-power wireless energy supply and micron-level flexible electrode arrays all require more than ten years of clinical and engineering data accumulation. Capital cannot catch up through short-term mergers and acquisitions or purchased technology, permanently locking the global industrial competition endgame in the next decade and building an ultra-long-term hardware moat.

3.2 三重递进终局重估路径：认知纠偏 + 商业兑现 + 范式永续溢价抬升

中文：结合 BCI 半导体 HALO 体系终局估值逻辑与当前全球资本市场跨行业认知偏差，全球 BCI 生物半导体资产将依托认知范式纠偏、商业化洼地回填、半导体终局永续溢价扩容三重递进式价值重估路径，完成跨行业、范式级系统性价值重构，开启 5-10 年长周期估值持续上行通道。三重路径层层递进、相互赋能、协同共振，形成不可逆长期价值抬升趋势，高度适配全球离岸长线主权、医疗绿色资本超长周期重估配置节奏。

English：Combined with the endgame valuation logic of BCI semiconductor HALO system and the current cross-industry cognitive deviations of the global capital market, global BCI bio-semiconductor assets will complete cross-industry and paradigm-level systematic value reconstruction relying on three progressive value revaluation paths of cognitive paradigm correction, commercial depression backfilling and sustainable semiconductor endgame premium expansion, opening a sustained upward valuation channel for 5-10 long cycles. The three paths are progressive, mutually empowering and synergistic, forming an irreversible long-term value upward trend, highly compatible with the ultra-long-cycle revaluation allocation rhythm of global offshore long-cycle sovereign and medical green capital.

3.2.1 第一重：跨行业认知偏差修复（短期估值快速纠偏）

中文：当前全球医药研究员统一沿用创新药、高值耗材 PEG 估值框架，对 BCI 生物半导体赛道形成跨行业系统性范式错配与深度认知折价。本轮短期估值修复核心驱动为投研范式全面重构，全球离岸长线资金将逐步摒弃基于患者池、临床入组、季度临床进度的浅层医药研判体系，全面切换至「通道容量 - 晶圆制程 - 封装良率」HALO 半导体长周期终局定价逻辑。成长天花板误判、硬件壁垒误判、产业赛道定性误判三大核心认知偏差将系统性修正，市场重新认知 BCI「半导体硬件本体、低折旧通道复利、分区域战略刚需、差异化垄断格局」硬核核心属性，完成短期估值快速纠偏，修复当前深度系统性折价空间。

English：At present, global medical researchers uniformly adopt the PEG valuation framework of innovative drugs and high-value consumables, resulting in cross-industry systematic paradigm mismatch and in-depth cognitive discount for BCI bio-semiconductor tracks. The core driver of this short-term valuation repair is the comprehensive reconstruction of investment research paradigms. Global offshore long-cycle funds will gradually abandon the shallow medical research system based on patient pool, clinical enrollment and quarterly clinical progress, and fully switch to the HALO semiconductor long-cycle endgame pricing logic of "channel capacity - wafer process - packaging yield". Three core cognitive deviations including growth ceiling misjudgment, hardware barrier misjudgment and industrial track qualitative misjudgment will be systematically corrected. The market will re-recognize the hardcore core attributes of BCI including "semiconductor hardware ontology, low-obsolescence channel compound interest, regional differentiated strategic rigid demand and differentiated monopoly pattern", realize rapid short-term valuation correction and repair the current deep systematic discount space.

3.2.2 第二重：商业化价值洼地回填（中期业绩持续兑现）

中文：全球各区域 BCI 梯队企业长期被资本市场割裂定价，中国微创视觉 BCI、美国千通道半侵入 BCI 估值显著低于同制程半导体芯片、高端医疗器械海外同业资产，形成全球高确定性跨境商业化价值洼地。伴随国内 NMPA 三类器械审批落地、湖南医保模式全国复制、海外 FDA PMA 商用通道放开、ETSI 国际 SEP 标准落地变现，国产替代、医疗刚需放量、标准专利收费三大产业红利持续释放，各梯队 BCI 企业订单、营收、经营性现金流稳步兑现，以实体商业化业绩为核心支撑，完成中长期维度估值与营收双向持续抬升，持续回填长期低估形成的价值洼地。

English：BCI echelon enterprises in various global regions have long been priced separately by the capital market. The valuation of China’s minimally invasive visual BCI and US thousand-channel semi-invasive BCI is significantly lower than overseas peer assets of semiconductor chips and high-end medical devices under the same process, forming a globally highly certain cross-border commercial value depression. With the implementation of domestic NMPA Class III medical device approval, national replication of Hunan medical insurance model, opening of overseas FDA PMA commercial channels and monetization of ETSI international SEP standards, three major industrial dividends including domestic substitution, volume expansion of medical rigid demand and standard patent charging will be continuously released. Orders, revenue and operating cash flow of BCI enterprises in all echelons will be steadily delivered, supported by physical commercial performance to complete the two-way sustained upward trend of valuation and revenue in the medium and long term, continuously backfilling the value depression formed by long-term underestimation.

3.2.3 第三重：半导体终局永续溢价抬升（十年长周期范式溢价）

中文：在短期认知修复、中期商业化业绩回填充分落地后，全球头部 BCI 硬核资产将迈入半导体终局永续溢价进阶阶段。依托全栈自研芯片硬件壁垒、通道摩尔定律复利成长、分区域全球差异化垄断、独家商业化支付闭环四大全国独有禀赋，头部 BCI 资产彻底脱离传统医药周期、医疗耗材内卷赛道，构建专属生物半导体超长周期离岸估值溢价体系。硬件准入永续溢价、通道复利成长溢价、区域格局垄断溢价、全球标准专利溢价四重红利长期持续释放，估值中枢实现十年维度持续性上行，完成从「阶段性估值修复」到「半导体终局永续溢价抬升」的跨行业范式跨越，正式确立生物半导体细分赛道全球离岸定价锚核心地位。

English：After the full implementation of short-term cognitive repair and medium-term commercial performance backfilling, global leading BCI hardcore assets will enter the advanced stage of sustainable semiconductor endgame premium. Relying on four exclusive endowments including full-stack self-developed chip hardware barriers, compound growth of channel Moore’s Law, differentiated global regional monopoly and exclusive commercial payment closed-loop, leading BCI assets will be completely separated from traditional medical cycles and medical consumable involution tracks, forming an exclusive ultra-long-term offshore valuation premium system for bio-semiconductors. Four major dividends of sustainable hardware access premium, channel compound growth premium, regional pattern monopoly premium and global standard patent premium will be continuously released in the long run. The valuation center will maintain a ten-year continuous upward trend, realizing the cross-industry paradigm leap from "phased valuation repair" to "sustainable semiconductor endgame premium uplift", and formally establishing the core position of global offshore pricing anchor in segmented bio-semiconductor tracks.

3.3 长周期估值横向对标：BCI 生物半导体 VS 传统医药 / 消费电子资产

中文：从 5-10 年长周期离岸定价维度横向对标，BCI 生物半导体硬核资产相较于创新药、高值医疗耗材、轻型消费电子资产，具备全方位无短板结构化估值优势，彻底颠覆全球券商传统医疗定价认知。

其一，周期属性差异化：传统医药资产高度依赖集采、医保政策、临床景气周期，盈利波动剧烈；消费电子跟随终端换机周期大幅起落；BCI 分区域锚定国防、民生医疗、通信标准三大永续刚需，跨周期稳健增值无大幅波动；

其二，资产折旧差异化：创新药、耗材临床迭代后价值持续衰减，消费电子硬件 3-5 年完全淘汰；BCI 半导体遵循制程积淀增值逻辑，通道容量、封装工艺、自研芯片壁垒逐年增厚，资产价值持续复利增值，趋近零折旧；

其三，竞争格局差异化：医药、消费电子赛道产能过剩、同质化内卷严重，价格战持续压缩利润；全球 BCI 美欧中三方战略完全错位，无全域同质化竞争，各自独享本土增量红利；

其四，成长确定性差异化：医药成长上限被患者池锁死，消费电子增长依赖终端新品催化；BCI 成长天花板由晶圆制程定义，每一代工艺迭代打开数倍增量空间，十年维度成长确定性显著领先；其五，离岸资金适配差异化：传统医药、消费电子仅适配波段交易、主题短线资金；BCI 兼具半导体硬科技长周期属性 + 医疗防御属性，高度适配全球主权基金、超长周期医疗绿色母基金、保险底仓配置资金，具备全球稀缺的跨行业超长线战略配置价值。

English：Horizontal comparison from the 5-10 year long-term offshore pricing dimension shows that BCI bio-semiconductor hardcore assets have all-round and flawless structured valuation advantages compared with innovative drugs, high-value medical consumables and light consumer electronics assets, completely subverting the traditional medical pricing cognition of global brokerages.First, cyclical attribute differentiation. Traditional medical assets are highly dependent on centralized procurement, medical insurance policies and clinical prosperity cycles with severe profit fluctuations; consumer electronics fluctuate drastically with terminal replacement cycles; BCI anchors three sustainable rigid demands of national defense, people’s livelihood medical treatment and communication standards by region, achieving stable cross-cycle value appreciation without sharp fluctuations.Second, asset depreciation differentiation. The value of innovative drugs and consumables continues to attenuate after clinical iteration, and consumer electronics hardware is completely eliminated in 3-5 years; BCI semiconductors follow the logic of process accumulation and appreciation. Channel capacity, packaging technology and self-developed chip barriers thicken year by year, and asset value continues to compound and appreciate with near-zero obsolescence.Third, competition pattern differentiation. Medical and consumer electronics tracks suffer from overcapacity and severe homogeneous involution, and price wars continuously compress profits; the three-party strategies of US, Europe and China in global BCI are completely staggered without full-domain homogeneous competition, each exclusively enjoying local incremental dividends.Fourth, growth certainty differentiation. The growth ceiling of medicine is locked by patient pool, and the growth of consumer electronics relies on new terminal product catalysts; the growth ceiling of BCI is defined by wafer processes, and each generation of process iteration opens several times of incremental space, with significantly leading growth certainty in the ten-year dimension.Fifth, offshore capital adaptation differentiation. Traditional medicine and consumer electronics are only suitable for band trading and short-term thematic capital; BCI integrates the long-cycle attribute of semiconductor hard technology and medical defensive attribute, highly adapted to global sovereign funds, ultra-long-cycle medical green fund of funds and insurance bottom-position allocation capital, possessing globally scarce cross-industry ultra-long-term strategic allocation value.

CHAPTER 4 核心结论与离岸顶配分层配置策略｜全球 BCI 生物半导体十年定价锚

4.1 白皮书终局四大核心范式结论

中文：综合臻研社三大原创顶配投研框架、BCI 通道 HALO 五星终局定价体系、三角验证十级产业风控体系全维度量化研判结果，本白皮书凝练四大跨行业终局核心结论，彻底重构全球离岸长线资本对 BCI 脑机接口产业的半导体维度全新定价范式与估值体系

。第一，赛道本体唯一性：BCI 本质是第三代生物半导体模组，医疗临床仅为首个商业化支付场景，全球唯一适配「通道摩尔定律 - 晶圆制程锚定」估值体系的医疗硬科技赛道，彻底区别于创新药、高值耗材、消费电子等传统周期内卷资产，是全球前沿生物半导体离岸定价核心承载赛道；

第二，全球竞争分层错位性：美、欧、中三方形成完全差异化终局竞争格局，美国垄断万通道高端半导体硬件、欧洲掌控全球通信标准 SEP 定价权、中国独家掌握微创模组 + 医保全链路商业化闭环，三级梯队赛道分工清晰，分别适配底仓、标准、防御、前瞻四类离岸资金配置诉求，短中长周期价值全覆盖无短板；

第三，资产估值永续低折旧属性：纯正自研 BCI 硬核生物半导体资产具备「全栈芯片重资产难复刻、通道迭代趋近零折旧、分区域国家战略永续刚需、全球差异化垄断无同质化内卷」终极禀赋，资产价值随制程迭代、工程工艺积淀持续复利增厚，无长期贬值、赛道出清风险，高度匹配全球超长周期离岸主权、绿色医疗机构核心配置需求；第四，跨行业重估趋势高确定性：当前全球券商医疗 PEG 定价体系存在底层逻辑系统性错配，全行业 BCI 生物半导体资产处于深度跨境认知价值洼地；短期半导体范式认知修复、中期全球商业化业绩兑现回填、长期通道制程永续溢价扩容三重路径共振，开启全球 BCI 产业 5-10 年长周期离岸估值系统性持续上行通道。

English：Based on the full-dimensional quantitative research results of Zhenyan Society’s three original top-tier investment research frameworks, BCI channel HALO five-star endgame pricing system and ten-tier triangular verification industrial risk control system, this whitepaper summarizes four cross-industry ultimate core conclusions, completely reconstructing a brand-new semiconductor dimensional pricing paradigm and valuation system of BCI industry for global offshore long-cycle capital.First, unique track ontology. BCI is essentially the third-generation bio-semiconductor module, and medical clinic is only the first commercial payment scenario. It is the only medical hard-tech track globally adapted to the valuation system of "channel Moore’s Law - wafer process anchoring", completely different from traditional cyclical involution assets such as innovative drugs, high-value consumables and consumer electronics, serving as the core carrier track for offshore pricing of global frontier bio-semiconductors.Second, differentiated hierarchical global competition pattern. The US, Europe and China form completely differentiated endgame competition patterns. The US monopolizes high-end ten-thousand-channel semiconductor hardware, Europe holds the SEP pricing power of global communication standards, and China exclusively masters the full-link commercial closed-loop of minimally invasive modules + medical insurance. The three-level echelon tracks have clear division of labor, respectively matching the allocation demands of four types of offshore capital including bottom-position, standard, defense and forward-looking, realizing full coverage of short, medium and long-term value without deficiencies.Third, sustainable low-obsolescence asset valuation attributes. Pure self-developed BCI hardcore bio-semiconductor assets have the ultimate endowments of "hard-to-replicate full-stack chip heavy assets, near-zero obsolescence with channel iteration, sustainable regional national strategic rigid demand and global differentiated monopoly without homogeneous involution". Asset value continues to compound and thicken with process iteration and engineering technology accumulation without long-term depreciation or track exit risks, highly matching the core allocation needs of global ultra-long-cycle offshore sovereign and green medical institutions.Fourth, high certainty of cross-industry revaluation trend. The current medical PEG pricing system of global brokerages has systematic mismatch of underlying logic, and BCI bio-semiconductor assets across the whole industry are in a deep cross-border cognitive value depression. The resonance of short-term semiconductor paradigm cognitive repair, medium-term global commercial performance backfilling and long-term sustainable channel-process premium expansion opens a systematic sustained upward offshore valuation channel for the global BCI industry for 5-10 long cycles.

4.2 分梯队超长周期离岸标准化分层配置策略

中文：基于 BCI 赛道 HALO 五星星级评级、三角验证十级产业垄断风控筛查、全球企业梯队分层特征、离岸长线资本配置偏好四大核心维度，针对全球主权创新基金、离岸医疗绿色母基金、跨国医疗养老金、保险超长周期权益资金、跨境硬科技对冲基金五大机构主体，搭建分层、分级、分周期标准化离岸顶配配置体系，精准匹配底仓永续硬件、中坚商业弹性、跨周期防御对冲、远期前瞻布局四大超长周期机构资金布局逻辑与配置诉求。

English：Based on four core dimensions including BCI track HALO five-star rating, ten-tier triangular verification industrial monopoly risk control screening, hierarchical characteristics of global enterprise echelons and allocation preference of offshore long-cycle capital, a standardized layered, graded and phased top-tier offshore allocation system is built for five major institutional entities including global sovereign innovation funds, offshore medical green fund of funds, cross-border medical pension funds, ultra-long-cycle insurance equity capital and cross-border hard-tech hedge funds, accurately matching the layout logic and allocation demands of four types of ultra-long-term institutional funds: sustainable hardware bottom position, medium commercial elasticity, cross-cycle defensive hedging and long-term forward layout.

4.2.1 底仓配置（五星万通道侵入式 BCI 赛道）：十年超长周期持有，赚取硬件垄断复利永续溢价

中文：适配资金类型：全球主权财富创新基金、离岸生物科技绿色母基金、一级市场长线产业配置资金、硬科技核心底仓资金。核心配置标的：美国五星万通道侵入式 BCI 龙头（Neuralink、Paradromics）。配置逻辑：两大赛道半导体四维定价因子全域满分，自研 VLSI 全栈 ASIC 芯片、65536 极限通道承载、EUV 先进封装、自动植入机器人四大硬件壁垒全球绝对垄断，通道摩尔迭代无上限；唯一短板为短期无医保支付闭环、规模化营收兑现周期长，无长期硬件衰减、技术被替代、赛道出清风险，是全球 BCI 赛道唯一具备十年永续离岸硬件溢价属性的压舱石底层资产。操作策略：采用十年维度超长周期底仓持有策略，完全超脱短期临床数据波动、一级市场估值轮动、全球市场板块震荡干扰，全程获取全栈芯片硬件准入永续溢价、通道摩尔复利成长溢价、高端半导体全球格局垄断溢价三重长期复利收益，作为离岸生物半导体投资组合核心压舱基石。

English：Applicable capital types: global sovereign wealth innovation funds, offshore biotech green fund of funds, primary market long-cycle industrial allocation capital, core hard-tech bottom-position capital.Core allocation targets: US five-star ten-thousand-channel invasive BCI leaders (Neuralink, Paradromics).Allocation logic: The two tracks achieve full scores in all four-dimensional semiconductor pricing factors, with absolute global monopoly of four major hardware barriers including self-developed full-stack VLSI ASIC chips, extreme carrying capacity of 65536 channels, EUV advanced packaging and automatic implantation robots, and no upper limit for channel Moore iteration. The only shortcoming is no closed-loop medical insurance payment in the short term and a long delivery cycle of large-scale revenue. There are no long-term risks of hardware attenuation, technological substitution or track exit, and it is the only ballast bottom asset in the global BCI track with ten-year sustainable offshore hardware premium attributes.Operation strategy: Adopt an ultra-long ten-year bottom-position holding strategy, completely ignoring short-term clinical data fluctuations, primary market valuation rotation and global market sector shock disturbances, and obtain three-fold long-term compound returns including sustainable hardware access premium of full-stack chips, channel Moore compound growth premium and global pattern monopoly premium of high-end semiconductors throughout the holding cycle, serving as the core ballast cornerstone of offshore bio-semiconductor investment portfolios.

4.2.2 中坚配置（四星半千通道微创 BCI 赛道）：中长期稳健持仓，兑现跨境商业化估值增量弹性

中文：适配资金类型：跨境中线硬科技机构资金、离岸医疗主题基金、一二级联动医疗产业资本、跨国医疗养老金配置资金。核心配置标的：美国半侵入商用 BCI 龙头 Precision；中国视觉微创 BCI 核心标的微智医疗 IMIE（256 通道临床落地、512 通道研发完成、1024-2048 通道【口述・向李】技术储备）。配置逻辑：赛道半导体硬件壁垒扎实稳固，通道容量 256-1024 千通道区间，国产替代、全球临床拓展空间充足；美国标的具备成熟 FDA 商用审批通道，中国微智医疗独家打通湖南医保支付全链路，微创贴附视网膜路线天然规避皮层穿刺生物相容性隐患，同时兼具十年长线硬件防御属性与中短期商业化落地估值弹性，精准匹配中线离岸资金「稳固组合底盘、提升综合收益、捕捉商业化增量红利」核心配置诉求。操作策略：长期锁定核心底仓持仓不动，依托 NMPA 三类器械证获批、全国医保模式复制、通道从 256 迭代至 1024 三大核心催化适度波段操作，持续兑现国产替代深化、国家海洋脑科学战略落地、晶圆制程迭代释放带来的离岸估值修复红利，同步获取稳健临床营收增长与跨境估值中枢抬升双重收益。

English：Applicable capital types: cross-border medium-term hard-tech institutional funds, offshore medical thematic funds, medical industrial capital with primary and secondary market linkage layout, cross-border medical pension allocation capital.Core allocation targets: US semi-invasive commercial BCI leader Precision; core target of China’s visual minimally invasive BCI Weizhi Medical IMIE (256 channels clinically implemented, 512 channels R&D completed, 1024-2048 channels technical reserve [Oral·Xiang-Li]).Allocation logic: The track has solid and robust semiconductor hardware barriers with channel capacity ranging from 256 to 1024 thousand channels, sufficient space for domestic substitution and global clinical expansion. US targets have mature FDA commercial approval channels, while China’s Weizhi Medical exclusively opens up the full-link Hunan medical insurance payment system. The minimally invasive retinal attachment route naturally avoids hidden biocompatibility dangers of cortical puncture, integrating ten-year long-term hardware defensive attributes and medium-short-term commercialization landing valuation elasticity, precisely matching the core allocation demands of medium-term offshore capital to stabilize portfolio fundamentals, improve comprehensive returns and capture commercial incremental dividends.Operation strategy: Maintain long-term fixed core bottom positions, and carry out moderate band operation relying on three core catalysts including NMPA Class III medical device approval, national replication of medical insurance model and channel iteration from 256 to 1024, continuously capture offshore valuation repair dividends brought by deepening domestic substitution, implementation of national marine brain science strategy and wafer process iteration, and simultaneously acquire dual income from steady clinical revenue growth and upward revision of cross-border valuation center.

4.2.3 防御配置（四星非侵入康复 BCI 赛道）：稳态长期持仓，穿越全球市场震荡对冲回撤

中文：适配资金类型：跨境稳健医疗配置资金、保险固收 + 权益组合配置资金、长线对冲基金底仓对冲资金、低波动离岸医疗母基金。核心配置标的：国内非侵入康复 BCI 龙头强脑科技 BrainCo。配置逻辑：赛道刚需康复医疗场景稳定，无颅内植入手术安全风险，临床审批节奏平缓可控，经营性现金流长期稳健；产业需求与宏观经济周期、全球科技板块剧烈波动弱关联，跨周期抗回撤防御属性极强。在全球半导体供应链波动、海外侵入式 BCI 临床安全事件、二级市场科创赛道大幅回调背景下，该梯队资产能够有效对冲组合净值回撤风险，依靠稳定康复器械现金流与国内民生医疗政策持续托底，提供可持续稳健防御收益，筑牢离岸投资组合安全底盘。操作策略：以稳态长线底仓持有为主，减少短期频繁波段交易，依托国内康复医疗市场稳步扩容、非侵入式 BCI 消费级产品放量两大长期确定性逻辑，赚取持续稳健的基本面增值现金流收益，作为组合对冲波动、控制净值回撤的核心防御板块。

English：Applicable capital types: cross-border stable medical allocation capital, insurance fixed income + equity portfolio allocation funds, long-cycle hedge fund bottom-position hedging capital, low-volatility offshore medical fund of funds.Core allocation target: domestic non-invasive rehabilitation BCI leader BrainCo.Allocation logic: The track has stable rigid-demand rehabilitation medical scenarios without intracranial implantation surgical safety risks, smooth and controllable clinical approval rhythm and long-term steady operating cash flow. Industrial demand has weak correlation with macroeconomic cycles and sharp fluctuations of global technology sectors, with outstanding cross-cycle drawdown-resistant defensive attributes. Against the backdrop of global semiconductor supply chain fluctuations, clinical safety incidents of overseas invasive BCI and sharp corrections of secondary market sci-tech tracks, assets in this echelon can effectively hedge portfolio net value drawdown risks, generate sustainable stable defensive returns relying on steady rehabilitation equipment cash flow and continuous support of domestic people’s livelihood medical policies, and consolidate the safety bottom of offshore investment portfolios.Operation strategy: Adopt a stable long-term bottom-position holding strategy and reduce frequent short-term band transactions. Rely on two long-term deterministic logics including steady expansion of domestic rehabilitation medical market and volume expansion of consumer-grade non-invasive BCI products to acquire sustained and stable fundamental value-added cash flow returns, serving as the core defensive sector for portfolio volatility hedging and net value drawdown control.

4.2.4 前瞻预埋配置（远期下一代生物半导体赛道）：小仓位长期预埋，捕捉十年维度范式跃迁超额收益

中文：适配资金类型：跨境前沿科技前瞻布局资金、全球主权基金创新试验仓位、一级市场硬科技孵化联动资本、全球生物半导体专项离岸主题基金。核心配置标的：微智医疗 AMD 全适应症拓展管线、Apple/Meta 消费级 BCI 原型研发主体、3nm CoWoS 万通道下一代植入 BCI 研发企业、ETSI 通信标准 SEP 专利卡位企业。配置逻辑：该类赛道依托全球独家海上临床试点、下一代先进封装工艺、THz 无线通信标准专利壁垒，产业技术迭代天花板极高，具备从专用医疗植入设备跨越至全民人机交互消费电子的范式升级潜力；当前整体处于产业早期培育阶段，短期营收兑现节奏平缓，但长期不受现有千通道 BCI 竞争格局约束，是离岸前瞻资金布局下一代脑机生物半导体革命、赚取远期技术范式重估超额溢价的稀缺核心标的。操作策略：初始小仓位长期预埋布局，分阶段动态加仓；伴随晶圆 3nm/7nm 制程落地、消费级 BCI 商业化试点、国际 SEP 标准落地收费三大产业里程碑持续抬升持仓仓位，完整捕捉远期芯片制程突破、全适应症临床落地、全球标准专利变现带来的超长周期迭代超额收益。

English：Applicable capital types: cross-border forward technology layout capital, global sovereign fund innovation test positions, primary market hard-tech incubation linkage capital, global bio-semiconductor special offshore thematic funds.Core allocation targets: Weizhi Medical AMD full-indication expansion pipeline, R&D entities of Apple/Meta consumer-grade BCI prototype, R&D enterprises of next-generation implantable BCI with ten-thousand channels under 3nm CoWoS process, enterprises with carded ETSI communication standard SEP patents.Allocation logic: Benefiting from global exclusive offshore clinical pilots, next-generation advanced packaging processes and THz wireless communication standard patent barriers, these tracks possess an ultra-high ceiling for industrial technical iteration and the potential of industrial upgrading from special medical implant equipment to national human-computer interaction consumer electronics. Currently in the overall early industrial cultivation stage with moderate short-term revenue delivery pace, they are free from constraints of the existing thousand-channel BCI competition pattern in the long run, acting as scarce core targets for offshore forward-looking capital to deploy the next-generation BCI bio-semiconductor revolution and capture excess premium of long-term technical paradigm revaluation.Operation strategy: Adopt a long-term forward layout strategy with initial small positions and dynamic position increase by stages. Continuously raise holding positions alongside three industrial milestones including implementation of 3nm/7nm wafer processes, commercial pilots of consumer-grade BCI and charging upon landing of international SEP standards, so as to fully capture ultra-long-cycle iterative excess returns brought by long-term chip process breakthroughs, full-indication clinical implementation and monetization of global standard patents.

4.3 专属三角验证十级终局风控体系终局说明

中文：本研究独创「技术 - 资本 - 政策」三角验证十级产业垄断一票否决终局风控体系，彻底颠覆全球券商医药赛道九级短期财务浅层风控逻辑，重构适配 BCI 生物半导体跨行业赛道专属的十年长周期产业维度风控新标准。传统医药机构风控体系根植于创新药、医疗器械临床赛道，仅聚焦短期财报毛利率、季度临床入组增速、资产负债现金流等表层财务指标，核心致命缺陷是「仅校验短期账面经营安全，完全忽略生物半导体赛道四大隐性十年终局长期风险」：高端 ADC / 定制 ASIC 半导体供应链断供、ETSI/ISO 国际标准 SEP 专利壁垒封锁、植入设备十年长期生物相容性衰减失效、本土医保政策全国复制不及预期。本体系在传统医药财务风控基础上，新增四大生物半导体专属终局风控红线，将风控研判维度从「单年度短期财务安全校验」升维至「十年产业永续芯片自研能力、全球标准专利壁垒稳固、商业化支付闭环可持续、长期临床生物相容性安全」四大终局核验标准，实现全球 BCI 全梯队企业穿透式、全周期跨产业风险筛查。所有入选离岸顶配配置池的标的，均通过十级产业垄断、晶圆制程迭代、SEP 标准专利、医保商业化闭环、长期临床安全五维全域交叉校验，无产业终局颠覆、核心硬件技术被替代、本土商业化闭环断裂、全球标准专利封锁四大致命长期风险，具备全球稀缺的超长周期离岸配置安全边际。

English：This research innovatively proposes the ten-tier industrial monopoly one-veto endgame risk control system based on Technology-Capital-Policy Triangular Verification, thoroughly subverting the shallow nine-tier short-term financial risk control logic of global brokerages’ pharmaceutical tracks and reconstructing exclusive ten-year long-cycle industrial dimension risk control standards adapted to cross-industry BCI bio-semiconductor tracks. Rooted in clinical tracks of innovative drugs and medical devices, the risk control system of traditional pharmaceutical institutions only focuses on superficial financial indicators such as short-term financial report gross profit margin, quarterly clinical enrollment growth rate and balance sheet cash flow, with a fatal core defect: it only verifies short-term book operation safety and completely ignores four implicit ten-year long-term endgame risks of bio-semiconductor tracks including supply chain cut-off of high-end ADC/customized ASIC semiconductors, blockade of ETSI/ISO international standard SEP patent barriers, attenuation and failure of implant equipment’s long-term biocompatibility within ten years, and lower-than-expected national replication of local medical insurance policies.On the basis of traditional pharmaceutical financial risk control, this system adds four exclusive endgame risk control red lines for bio-semiconductors, upgrading risk control judgment dimension from single-year short-term financial safety verification to four endgame verification standards including ten-year sustainable self-developed chip capability, stable global standard patent barriers, sustainable commercial payment closed-loop and long-term clinical biocompatibility safety, realizing penetrating and full-cycle cross-industry risk screening for all echelon enterprises of global BCI. All targets included in the offshore top-tier allocation pool have passed full-dimensional cross-verification of ten-tier industrial monopoly, wafer process iteration, SEP standard patents, medical insurance commercial closed-loop and long-term clinical safety, without four fatal long-term risks including industrial endgame subversion, substitution of core hardware technology, rupture of local commercial closed-loop and blockade of global standard patents, possessing globally scarce ultra-long-cycle offshore allocation safety margins.

4.4 跨行业范式终极总结：全球 BCI 生物半导体离岸定价权历史性转移

中文：纵观全球前沿医疗科技离岸定价体系迭代历程，过去十年全球券商统一依托创新药、医疗器械短期临床复盘估值范式垄断医疗赛道定价话语权，依靠 PEG、患者池、临床进度浅层指标主导全球医疗资本定价逻辑，形成固化医药定价霸权。但这套老旧临床估值体系完全不适配 BCI 生物半导体重资产、通道复利、分区域差异化垄断、医保闭环刚需的跨行业硬核资产，持续产生系统性、结构性、持续性的跨境估值认知错配与长期估值压制。本研究落地三大原创顶配投研体系，彻底颠覆全球券商传统医药临床定价老旧范式，完成从「西方医药临床短期 PEG 定价」到「中国本土半导体通道终局长周期定价」的跨行业历史性范式切换，搭建专属全球 BCI 生物半导体赛道的长周期、低折旧、差异化垄断离岸全新估值体系。以微智医疗为代表的中国微创医保闭环 BCI 资产、美国万通道高端侵入式 BCI 硬件龙头，将共同构筑全球生物半导体细分赛道双重离岸定价锚，终结全球券商单一临床维度垄断 BCI 资产定价的旧时代，正式开启全球长线离岸主权、绿色医疗资本基于晶圆制程、通道摩尔复利、全球标准专利、分区域商业化闭环四维终局思维的全新跨行业配置新时代。

English：Reviewing the iteration process of the offshore pricing system for global frontier medical technology, global brokerages have monopolized the pricing discourse power of medical tracks relying on the short-term clinical retrospective valuation paradigm of innovative drugs and medical devices in the past decade, dominating the global medical capital pricing logic by shallow indicators including PEG, patient pool and clinical progress, forming solidified pharmaceutical pricing hegemony. However, this outdated clinical valuation system is completely incompatible with cross-industry hardcore assets of BCI bio-semiconductors featuring heavy assets, channel compound interest, differentiated regional monopoly and closed-loop medical insurance rigid demand, continuously generating systematic, structural and persistent cross-border valuation cognitive mismatch and long-term valuation suppression.This research launches three original top-tier investment research systems, thoroughly subverting the outdated traditional pharmaceutical clinical pricing paradigm of global brokerages, completing the cross-industry historic paradigm shift from "Western short-term PEG pricing based on pharmaceutical clinics" to "China’s local long-cycle endgame pricing based on semiconductor channels", and building a brand-new offshore valuation system with long cycle, low obsolescence and differentiated monopoly exclusive to the global BCI bio-semiconductor track. China’s minimally invasive medical insurance closed-loop BCI assets represented by Weizhi Medical and US high-end invasive BCI hardware leaders with ten-thousand channels will jointly build dual offshore pricing anchors for segmented global bio-semiconductor tracks, end the old era when global brokerages monopolized BCI asset pricing from a single clinical dimension, and officially usher in a new cross-industry allocation era for global long-cycle offshore sovereign and green medical capital based on four-dimensional endgame thinking of wafer processes, channel Moore compound interest, global standard patents and differentiated regional commercial closed-loops.

本内容由渣学院臻研社战略组整理输出，仅为产业逻辑研究与市场复盘交流使用，不构成任何个股投资建议、交易指导及收益承诺。

文中所有产业政策、行业催化、赛道逻辑均来自公开信息与合理推演，不具备绝对准确性与时效性。所有“动态触发信号”“仓位配置建议”“操作指引”均为基于特定市场假设的战略推演，实际市场运行存在极高不确定性。

二级市场投资存在极高风险，包括但不限于政策变动、产业落地不及预期、市场情绪波动、流动性变化、黑天鹅事件等风险。所有交易决策均由投资者自主判断、自主执行、自行承担风险。本团队不承担任何依据本文内容产生的投资盈亏及相关法律责任。

©2026 广东森投锦海科技有限公司·臻研社保留全部著作权。本报告所有研究框架、测算模型、产业逻辑、图文内容及研判观点均为机构独家原创，知识产权归属本公司所有，受《中华人民共和国著作权法》保护。未经书面盖章授权，任何主体不得转载、摘抄、篡改、二次改编及商用传播，本机构保留全部法律追责权利。本报告仅为专业机构产业研究参考，不构成任何投资建议、盈利承诺及医疗诊疗指导，前瞻性研判存在市场变量波动，使用者决策风险自负，仅限合规机构内部研读，适用中华人民共和国法律。

Institutional Compliance Statement：This document is for institutional professional reference only, not for public investment recommendation. All industrial judgments and paradigm pricing are based on public industrial logic and fundamental deduction. Capital market valuation is affected by multi-dimensional variables, and institutional investors shall make independent judgments based on their own risk assessment system